Adam Keeney , Head of Corporate Development, said the acquisition would add “two best-in-class products” to Biogen’s growth portfolio: Syfovre in geographic atrophy (GA) and Empaveli across rare hematology and kidney diseases.Viehbacher laid out several criteria he said would need to be met for an acquisition, including staying aligned with Biogen’s broadened focus beyond neuroscience into “neurology, immunology, and rare diseases,” avoiding excessive balance sheet stretch, keeping the deal size around “$5 ...

Market Overview - The U.S. stock market opened with significant bullish momentum on March 31st, 2026, driven by cooling geopolitical tensions and a major acquisition in the pharmaceutical sector [1] - The "fear gauge" VIX dropped nearly 10% to 27.57, indicating a renewed appetite for risk among investors [1] Market Indexes Performance - Major market indexes showed broad-based strength, with the NASDAQ rising 415.24 points, or 2.00%, to 21,209.88 [2] - The S&P 500 climbed 1.56% to 6,442.45, surpassing the 6,400 threshold [2] - The Dow Jones Industrial Average increased by 599.64 points, or 1.33%, to 45,815.78 [2] - Small-cap stocks outperformed larger counterparts, with the Russell 2000 jumping 2.07% to 2,464.03 [3] Commodities Market - Gold Futures gained 1.60%, trading at $4,630.50 per ounce, continuing its historic run [3] - Crude Oil Futures stabilized at $102.48, down 0.39%, amid reports of potential de-escalation in Middle Eastern hostilities [3] Economic Indicators - The February Job Openings and Labor Turnover Survey (JOLTS) reported job openings at 6.9 million, while the hires rate dipped to 3.1%, the lowest since early 2020 [4] - Investors are awaiting the Consumer Confidence index for March and Nike's third-quarter fiscal 2026 financial results [5] Corporate Developments - Biogen announced a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion, paying $41.00 per share, leading to a 136.4% increase in Apellis' stock price to $40.40 [6] - The acquisition is expected to enhance Biogen's portfolio in rare diseases and immunology [6] - The Biotech ETF rose by 6.47% following the acquisition news, with Centessa Pharmaceuticals increasing by 45.2% [7] - McCormick & Company reported Q1 2026 earnings meeting expectations with an EPS of $0.61 [8] Market Sentiment - The market sentiment remains "risk-on" despite a 1.60% decline in the energy sector, as investors focus on the Federal Reserve's next moves and the impact of stabilizing oil prices on inflation [9]

Biogen Business Update Call Summary Company and Industry Overview - **Company**: Biogen - **Acquisition Target**: Apellis Pharmaceuticals - **Industry**: Biotechnology, specifically focusing on immunology and rare diseases Key Points and Arguments Acquisition Rationale - Biogen is acquiring Apellis for approximately **$5.6 billion** in cash, with an additional contingent value tied to sales performance of Apellis' products [20][21] - The acquisition aligns with Biogen's strategy to expand beyond neuroscience into immunology and rare diseases, enhancing its growth portfolio [5][14] - Apellis' products, **Syfovre** and **Empaveli**, are seen as best-in-class therapies addressing significant unmet needs in immune-mediated retinal disease and rare hematology [14][15] Product Insights - **Syfovre**: First FDA-approved therapy for Geographic Atrophy, targeting a market of **1.5 million** diagnosed patients in the U.S., with less than **10%** currently treated [15][30] - **Empaveli**: Approved for PNH and two rare kidney diseases (C3G and ICMPGN), with significant growth potential as it is the only FDA-approved therapy for these conditions [16][17] - Biogen expects combined revenue growth from these products in the **mid- to high teens** percentage range over the next two years [21][22] Strategic Fit and Market Position - The acquisition is viewed as a strategic fit, enhancing Biogen's capabilities in nephrology and immunology, with a focus on leveraging Apellis' established commercial infrastructure [19][22] - Biogen aims to utilize Apellis' sales and marketing team to accelerate the launch of its own pipeline product, **felzartamab**, in kidney disease [19][22] Financial Considerations - The acquisition will be financed through cash on hand, revolver borrowings, and a bank term loan, with expected financing costs of **$120 million-$130 million** in 2026 and 2027 [20] - Biogen anticipates being able to repay the acquisition-related debt by the end of **2027**, maintaining strategic flexibility [20][23] - The deal is expected to be accretive starting in **2027**, significantly increasing Biogen's non-GAAP diluted EPS CAGR through the end of the decade [23] Competitive Landscape - Biogen acknowledges the competitive nature of the markets for both Syfovre and Empaveli, with ongoing investments from competitors like Astellas and Novartis [30][31] - Despite competition, Biogen believes Syfovre has a competitive advantage due to its best-in-class profile and the potential for increased patient engagement [30][31] Risks and Challenges - Potential risks include variability in patient activation and retention rates, particularly for Syfovre, where **50%** of patients may drop off treatment [45][66] - Long-term forecasts for both products are subject to uncertainties in epidemiology and market dynamics, particularly for IC-MPGN [66] Future Outlook - Biogen remains committed to its neuroscience portfolio while strategically expanding into immunology and rare diseases [81][84] - The company plans to update its full-year **2026** financial guidance in the upcoming earnings report [24] Additional Important Insights - The acquisition process involved extensive market research and due diligence, ensuring alignment with Biogen's strategic goals [25][70] - Biogen's leadership emphasizes the importance of patient education and engagement to improve treatment adherence and market penetration for both products [45][46] - The integration of Apellis' team is expected to enhance Biogen's capabilities in nephrology and support the launch of future products [19][90]

Core Insights - Biogen has acquired Apellis Pharmaceuticals for $5.6 billion, enhancing its drug portfolio with two approved medications [1] - The acquisition has significantly boosted Apellis' stock, which saw a triple-digit increase following the announcement [1] Company Overview - Biogen's acquisition of Apellis adds Empaveli and Syfovre to its pipeline, with Empaveli approved for treating three conditions, including two rare kidney diseases, and Syfovre targeting an eye disease [1] - Last year, the combined sales of Empaveli and Syfovre contributed to Apellis' revenue growth, indicating strong market potential for these drugs [1]

Core Viewpoint - Apellis Pharmaceuticals has experienced a decline in share price by approximately 17.3% since its last earnings report, underperforming the S&P 500, raising questions about the continuation of this negative trend leading up to the next earnings release [1][2]. Financial Performance - In Q4 2025, Apellis reported a loss of $0.47 per share, which was wider than the Zacks Consensus Estimate of a loss of $0.39, compared to a loss of $0.29 in the same quarter the previous year [3]. - Total revenues for Q4 were $199.9 million, surpassing the Zacks Consensus Estimate of $194 million, but reflecting a 6% year-over-year decline from $212.5 million in the prior year due to lower Syfovre revenues [4]. - Syfovre sales amounted to $155.2 million in Q4, an 8% decrease year-over-year, although it slightly exceeded the Zacks Consensus Estimate of $154.2 million [5]. - Empaveli generated sales of $35.1 million, marking a 50% increase from the previous year, and also beating the Zacks Consensus Estimate of $28.5 million [7]. - Licensing and other revenues fell to $9.6 million, showing a significant year-over-year decline [8]. Cost Management - Research and development expenses decreased by 3% year-over-year to $74.2 million, attributed to lower program-specific external costs and reduced personnel costs [8]. - Selling, general, and administrative expenses rose by 21% year-over-year to $147.1 million, driven by increased professional fees and personnel costs, partially offset by a decrease in general commercial activities [9]. Cash Position - As of December 31, 2025, Apellis had cash, cash equivalents, and marketable securities totaling $466.2 million, down from $479.2 million as of September 30, 2025, with expectations that this balance will support operations until profitability is achieved [10]. Annual Results - For the full year 2025, Apellis reported total revenues of $1.0 billion, a 28% increase year-over-year, exceeding the Zacks Consensus Estimate of $998.3 million, which included a one-time $275 million upfront payment from a royalty repurchase agreement [11]. - The company reported earnings per share of $0.20 for 2025, compared to a loss of $1.60 per share in 2024, although this figure missed the Zacks Consensus Estimate of $0.24 [11]. Market Outlook - Estimates for Apellis have been trending upward, with a consensus estimate shift of 13.86% over the past month, indicating positive sentiment [12]. - The company holds a Zacks Rank 3 (Hold), suggesting an expectation of an in-line return in the coming months [14]. Industry Comparison - Apellis operates within the Zacks Medical - Biomedical and Genetics industry, where Royalty Pharma, a peer, reported revenues of $874 million for the last quarter, reflecting a year-over-year increase of 17.8% [15].

Group 1 - Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is identified as one of the 10 most shorted biotech stocks to buy according to hedge funds [1] - JPMorgan increased the price target on Apellis from $36 to $37, maintaining an Overweight rating with an adjusted upside potential of over 84% [1] - A recent survey of 23 nephrologists indicated that Apellis' medication for Paroxysmal Nocturnal Hemoglobinuria, Empaveli, is positioned for significant market share gains [1] Group 2 - Wedbush noted that Apellis' fourth-quarter report aligned with consensus expectations, with key results preannounced in January [3] - Management expects Syfovre pricing to remain flat through fiscal year 2026, indicating limited growth potential [3] - Apellis is focused on developing treatments for rare blood disorders and vision-threatening eye conditions, with innovative treatments in development, including gene editing approaches [3]

Core Viewpoint - Wedbush has lowered the price target for Apellis (APLS) to $18 from $20 while maintaining a Neutral rating on the shares [1] Financial Performance - The Q4 report from Apellis was largely as anticipated, with the company having preannounced key results in January [1] - Management expects flat Syfovre pricing into FY26, indicating limited growth prospects [1]

Core Insights - Apellis Pharmaceuticals reported a fourth-quarter 2025 loss of 47 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 39 cents, compared to a loss of 29 cents in the same quarter last year [1][7] Financial Performance - Total revenues for the fourth quarter were $199.9 million, exceeding the Zacks Consensus Estimate of $194 million, but down 6% year-over-year from $212.5 million in the previous year [2] - Revenues included product sales from Empaveli and Syfovre, along with licensing and other revenues from a collaboration agreement with Sobi [3] - Syfovre sales were $155.2 million, an 8% decline year-over-year, although it slightly surpassed the Zacks Consensus Estimate of $154.2 million [4] - Empaveli recorded sales of $35.1 million, a 50% increase from the previous year, driven by early launch momentum in C3G and IC-MPGN, and also beat the Zacks Consensus Estimate of $28.5 million [9] Market Position and Product Performance - Syfovre holds approximately 60% market share in geographic atrophy treatment, with total injections growing about 17% year-over-year despite the revenue decline attributed to increased use of free goods [5] - Apellis delivered over 89,000 commercial vials and nearly 13,000 samples of Syfovre to doctors in the reported quarter [5] Cost Management - Research and development expenses decreased by 3% year-over-year to $74.2 million, attributed to lower program-specific external costs and personnel costs [10] - Selling, general, and administrative expenses rose by 21% year-over-year to $147.1 million, driven by higher professional fees and personnel costs [11] Cash Position - As of December 31, 2025, Apellis had cash, cash equivalents, and marketable securities totaling $466.2 million, down from $479.2 million as of September 30, 2025, with expectations that this will fund operations to profitability [12] Annual Performance - For the full year 2025, Apellis reported total revenues of $1.0 billion, a 28% increase year-over-year, surpassing the Zacks Consensus Estimate of $998.3 million, which included a one-time $275 million upfront payment from a royalty repurchase agreement [14] - The company reported earnings per share of 20 cents for 2025, compared to a loss of $1.60 per share in 2024, although it missed the Zacks Consensus Estimate of 24 cents [14] Pipeline Developments - Apellis has initiated two pivotal phase III studies of Empaveli for focal segmental glomerulosclerosis and delayed graft function, both of which are rare kidney diseases with no approved therapies [16] - A mid-stage multi-dose study of siRNA candidate APL-3007 in combination with Syfovre is ongoing, with top-line data expected in 2027 [17]

Core Insights - Apellis Pharmaceuticals reported a year of disciplined execution and foundation building, driven by strong demand for its geographic atrophy therapy Syfovre and the early launch of Empaveli in rare kidney diseases [5] Financial Performance - Total revenue for the fourth quarter was $200 million, with full-year revenue reaching $1.0 billion for 2025, including a one-time $275 million payment related to a royalty repurchase agreement [4] - Syfovre generated $155 million in net product revenue for the fourth quarter and $587 million for the full year, with total injections increasing approximately 17% year-over-year [3][2] - Empaveli achieved $35 million in U.S. net product revenue in the fourth quarter and $102 million for the full year 2025, with over 5% market penetration after its first full quarter [3][9] Product Developments - The company is working on a prefilled syringe for Syfovre, with regulatory submission expected in the first half of 2026, aimed at improving convenience in retina clinics [7][8] - An AI-enabled tool called Functional OCT is being developed to visualize functional benefits in geographic atrophy, with plans for research use in the second half of 2026 [7][8] Market Position and Strategy - Syfovre continues to lead the geographic atrophy market, with strong payer coverage and preferred status across various plans [2] - The company is focusing on expanding patient identification and diagnosis through targeted medical education and increasing urgency for earlier treatment [13] Pipeline Updates - Apellis has initiated pivotal trials for Empaveli in focal segmental glomerulosclerosis and delayed graft function, addressing high unmet needs in kidney indications [11] - The company is also advancing earlier-stage programs, including a Phase 2 combination study with Syfovre and APL-3007, with top-line data expected in 2027 [14] Financial Position - Operating expenses for the fourth quarter were $251 million, consistent with the previous year, and the company ended 2025 with $466 million in cash and cash equivalents, providing flexibility for future operations [11] - Apellis has approximately $94 million of convertible debt maturing in September and is evaluating alternatives to address this obligation [12]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $200 million, and for the full year 2025, it was $1 billion, which included a one-time $275 million upfront payment from the Sobi royalty repurchase agreement [20] - Syfovre net product revenue for Q4 was $155 million and $587 million for the full year 2025, with total injections growing approximately 17% year-over-year despite a modest decline in revenue due to elevated use of free goods [11][20] - Empaveli reported U.S. net product revenue of $35 million for Q4 and $102 million for the full year 2025, with a market penetration of over 5% after its first full quarter [22][9] Business Line Data and Key Metrics Changes - Syfovre continues to lead the geographic atrophy (GA) market, with strong physician and patient demand, and is expected to remain a stable revenue stream through 2026 [7][11] - Empaveli's launch trajectory is progressing well, with strong early market receptivity and a growing patient pipeline, particularly in C3G and primary IC-MPGN [8][12] - The company is advancing pivotal trials in nephrology for focal segmental glomerulosclerosis and delayed graft function, expanding the Empaveli franchise [10][18] Market Data and Key Metrics Changes - The company expects to strengthen Syfovre's leadership in geographic atrophy and drive growth with Empaveli across rare kidney diseases [7] - Empaveli's strong efficacy and safety profile are driving adoption, with expectations that it could ultimately be used by up to 50% of the estimated 5,000 U.S. patient population for C3G and primary IC-MPGN [9][15] Company Strategy and Development Direction - The company is focused on three strategic pillars: strengthening Syfovre's leadership, driving growth with Empaveli, and advancing an innovative pipeline [7] - The introduction of a best-in-class prefilled syringe and an AI-enabled approach for Syfovre is aimed at improving treatment accessibility and workflow efficiency [8][10] - The company aims to self-fund its pipeline and drive long-term value through disciplined financial execution [10][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term value creation potential of the company, emphasizing a strong balance sheet and disciplined execution [5][25] - The management highlighted the importance of patient access and the evolving dynamics of free goods utilization as third-party programs resume activity [21][57] - The company anticipates modest inventory reduction in Q1 2026 alongside typical seasonal dynamics, with a focus on maintaining a stable net price through the year [21][64] Other Important Information - The company ended 2025 with $466 million in cash and cash equivalents, providing substantial flexibility to fund operations [23] - A $25 million milestone payment was triggered by Sobi's European Commission approval for Aspaveli in C3G and primary IC-MPGN [23] Q&A Session Summary Question: Empaveli launch and growth potential - Management noted that Empaveli is on a clear path to blockbuster status, with a focus on broadening accounts and improving patient identification [29][30] Question: Syfovre five-year data significance - The five-year GALE data shows significant benefits in delaying progression of geographic atrophy, which may lead to earlier treatment for patients [34][36] Question: Empaveli penetration timeline - Management expects a steady ramp in penetration, with a focus on pediatric and post-transplant patients as key growth areas [39][40] Question: Prefilled syringe impact - The prefilled syringe is expected to enhance practice efficiency and support broader adoption of Syfovre [50][52] Question: Free goods dynamics - Management emphasized the commitment to patient access through free goods, which may impact new patient onboarding [97][98]